Compare · ABBV vs RANI
ABBV vs RANI
Side-by-side comparison of AbbVie Inc. (ABBV) and Rani Therapeutics Holdings Inc. (RANI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and RANI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $443.36B, about 4623.2x RANI ($95.9M).
- Over the past year, ABBV is up 27.2% and RANI is up 43.8% - RANI leads by 16.6 points.
- RANI has been more active in the news (8 items in the past 4 weeks vs 7 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 13 for RANI).
- Company
- AbbVie Inc.
- Rani Therapeutics Holdings Inc.
- Price
- $250.88-2.57%
- $0.78-5.46%
- Market cap
- $443.36B
- $95.9M
- 1M return
- -0.08%
- +1.67%
- 1Y return
- +27.25%
- +43.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2021
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 13
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Latest ABBV
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Second-Quarter 2026 Financial Results
- JUVÉDERM® Day Returns to U.S. on August 19
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Latest RANI
- Director Imran Mir A bought $24,840 worth of shares (36,000 units at $0.69), increasing direct ownership by 2% to 2,119,334 units (SEC Form 4)
- Chief Technical Officer Javadi Alireza sold $301 worth of shares (386 units at $0.78) and covered exercise/tax liability with 309 shares, decreasing direct ownership by 7% to 9,380 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Imran Talat bought $25,193 worth of shares (35,000 units at $0.72), increasing direct ownership by 8% to 469,736 units (SEC Form 4)
- Chief Executive Officer Imran Talat sold $11,300 worth of shares (8,014 units at $1.41) and covered exercise/tax liability with 52,001 shares, decreasing direct ownership by 12% to 434,736 units (SEC Form 4) (withholding obligation)
- SEC Form 4 filed by Chief Financial Officer Maestas Nicholas
- Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-8 filed by Rani Therapeutics Holdings Inc.
- Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
- Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
- SEC Form 3 filed by new insider Maestas Nicholas